Get the Stockscreener App
44.95
0.27%
0.12
After Hours:
44.95
Protagonist Therapeutics Inc stock is traded at $44.95, with a volume of 556.66K.
It is up +0.27% in the last 24 hours and down -4.89% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$44.83
Open:
$44.88
24h Volume:
556.66K
Relative Volume:
0.85
Market Cap:
$2.69B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
-16.77
EPS:
-2.68
Net Cash Flow:
$230.85M
1W Performance:
+10.58%
1M Performance:
-4.89%
6M Performance:
+47.81%
1Y Performance:
+158.04%
1-Day Range:
$43.80
$45.60
1-Week Range:
$40.72
$48.29
52-Week Range:
$17.13
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
44.95 | 2.69B | 45.48M | 169.95M | 230.85M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics' chief medical officer sells $1.41 million in stock - Investing.com
Protagonist Therapeutics chief development officer sells $5.6 million in stock - Investing.com
11,336 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Advantage Alpha Capital Partners LP - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Objective long/short (PTGX) Report - Stock Traders Daily
Algert Global LLC Sells 36,400 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Eagle Asset Management Inc. Lowers Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Victory Capital Management Inc. Has $5.89 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics selects IL-17 antagonist as development candidate - BioWorld Online
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 - AccessWire
Protagonist Therapeutics CEO to Present at Evercore ISI Healthcare Conference | PTGX Stock News - StockTitan
Pacer Advisors Inc. Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate - AccessWire
Protagonist's New IL-17 Drug Shows 100x Potency vs Current Treatments in Preclinical Data | PTGX Stock News - StockTitan
Wedbush Expects Higher Earnings for Protagonist Therapeutics - MarketBeat
Quest Partners LLC Increases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist takes center stage with Phase III fillip - The Pharma Letter
Protagonist Therapeutics' chief medical officer sells $78,107 in stock By Investing.com - Investing.com Australia
Protagonist Therapeutics' chief medical officer sells $78,107 in stock - Investing.com
New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data - BioCentury
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap DownHere's Why - MarketBeat
Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online
Protagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at Wedbush - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - Brazosport Facts
Protagonist Therapeutics to Unveil New Oral IL-17 Drug Candidate, Share Key Study Data | PTGX Stock News - StockTitan
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis - WSIL TV
Protagonist Therapeutics Enters Oversold Territory (PTGX) - Nasdaq
Protagonist's Psoriasis Drug Shows 74% Success Rate, Secures $165M Milestone Payment | PTGX Stock News - StockTitan
Janney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Amalgamated Bank Buys 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Amalgamated Bank Acquires 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
What is HC Wainwright’s Forecast for PTGX FY2024 Earnings? - Defense World
HC Wainwright Analysts Increase Earnings Estimates for PTGX - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for PTGX - Defense World
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
HC Wainwright Issues Pessimistic Estimate for PTGX Earnings - MarketBeat
US Bancorp DE Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright - MarketBeat
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates - MSN
New York State Teachers Retirement System Invests $1.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
New York State Teachers Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High – Should You Buy? - Defense World
Creative Planning Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
What is Wedbush’s Forecast for PTGX Q3 Earnings? - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighWhat's Next? - MarketBeat
Protagonist Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK
What is Wedbush's Estimate for PTGX Q3 Earnings? - MarketBeat
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):